ROBERT GUEVARA: Open Payments
NPI 1447310776 · EDINBURG, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,130 in 34 payments from 10 companies in 2025. Trend: 2023 $754 · 2024 $1,054 · 2025 $1,130
Food & beverage: $1,130
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $273 |
| Alkermes, Inc. | 11 | $241 |
| Otsuka America Pharmaceutical, Inc. | 4 | $190 |
| Neurocrine BioSciences, Inc. | 2 | $160 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $153 |
| Vanda Pharmaceuticals Inc. | 2 | $43 |
| ABBVIE INC. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Medline Industries LP | 1 | $17 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: REXULTI, UZEDY, INGREZZA, CAPLYTA, LYBALVI, ARISTADA, AUSTEDO XR, FANAPT.
Industry payments across TX — which companies pay providers there.
